In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RWE: The EMA's View

Executive Summary

The European Medicines Agency outlines the difficulties that impact regulators' ability to access and analyze real-world data.

The European Medicines Agency believes that real-world evidence is important for making many decisions about a medicine. It helps support pharmacovigilance activities and the assessment of safety signals, and it can also help measure the impact of any regulatory measures undertaken, says the agency. Such evidence also enables a better understanding of a medicine's risk-benefit balance and its effectiveness as well as informs HTA and health care utilization decisions. These activities apply to a wide range of medicines, including authorized medicines, innovative medicines, orphan medicines and medicines included in Adaptive Pathways. The agency says it sees a wide range of RWE collected from numerous sources, including e-health records, registries, hospital records and insurance data. Meanwhile, data from biobank, genomic and digital phenotyping information are increasingly being integrated into real-world evidence data sets.

Nevertheless, regulators face a number of difficulties that impact their ability to access and analyze real-world data. According to the EMA, these include:

  • fragmentation and lack of interoperability of resources
  • governance issues
  • privacy concerns
  • inadequate use of methods for integrating and analyzing heterogeneous data
  • underuse of technological advances
  • a lack of cross-border collaborations and sustained funding mechanisms for securing access to real-world data and then for analyzing it

It is therefore not surprising that the agency is calling for a "framework that provides the EU regulatory network with access to and analysis of an extensive range of multinational real-world data." This framework, says the EMA, should involve the development of "sustainable multi-stakeholder governance and funding mechanisms; a comprehensive characterization of EU-wide sources of real-world evidence; and identification or development of methods to integrate and analyze data and collaboration across stakeholders and borders."

Advertisement

Related Content

Real-World Evidence And The Quest For European Market Access

Topics

Advertisement
UsernamePublicRestriction

Register

IV004970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel